Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. International clinical psychopharmacology [Int Clin Psychopharmacol] Journal article | | Title | Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. | | Author(s) | Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, Tallawy HE, Danaci AE, Lowe W, Karayal ON | | Institution | aDepartment of Psychiatry, Dokuz Eylül University School of Medicine, Balçova-Izmir bDepartment of Psychiatry, Uludag University Medical School, Gorukle, Bursa cDepartment of Psychiatry, Celal Bayar University, Medical School, Manisa dDepartment of Psychiatry, Istanbul University, Istanbul Medical School, Istanbul, Turkey eDar Al Ajaza Al Islamyah Hospital, Beirut, Lebanon fNoordheuwel, Krugersdorp, Gauteng, South Africa gSismanoglion General Hospital, Department of Psychiatry, Athens, Greece hDepartment of Psychiatry, Assiut University, Medical School, Assiut, Egypt iPfizer Inc., New York, New York, USA. | | Source | Int Clin Psychopharmacol 2009 Jun 15. | | Abstract | To compare the effectiveness of a switch from haloperidol (N=99), olanzapine (N=82), or risperidone (N=104) to 12 weeks of treatment with 80-160 mg/day ziprasidone in patients with stable schizophrenia or schizoaffective disorder. Stable outpatients with persistent symptoms or troublesome side effects were switched using one of three 1-week taper/switch strategies as determined by the investigator. Efficacy was assessed using the Brief Psychiatric Rating Scale score, Clinical Global Impression, Positive and Negative Symptom Scale, Montgomery-Asberg Depression Rating Scale, and the Global Assessment of Functioning Scale, and tolerability by using standard measures of weight change, extrapyramidal symptoms, and laboratory findings. Suboptimal efficacy was the primary reason for switching. The preferred switch strategy was immediate discontinuation, and the preferred dosing regimen was 120 mg/day. Completer rates were 68, 60, and 86% in the haloperidol, risperidone, and olanzapine pre-switch groups, respectively. At week 12, a switch to ziprasidone resulted in statistically significant improvement from baseline on the Brief Psychiatric Rating Scale score, Clinical Global Impression-Improvement, Positive and Negative Symptom Scale, and Global Assessment of Functioning scales, reduction in extrapyramidal symptoms and a neutral impact on metabolic parameters. Switch from olanzapine and risperidone resulted in weight reduction and from haloperidol in some weight increase. In conclusion, oral ziprasidone of 80-160 mg/day with food was a clinically valuable treatment option for stable patients with schizophrenia or schizoaffective disorder experiencing suboptimal efficacy or poor tolerability with haloperidol, olanzapine, or risperidone. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19531959 |
|
|
| |
Advertise on this site.
| | |
|
